Navinci Diagnostics

Executive Summary

Navinci Diagnostics is a Swedish biotech company founded in 2017 that specializes in innovative in situ proximity ligation assay (isPLA)-based solutions for spatial proteomics. Its proprietary Naveni® technology enables precise, multiplexed detection of protein-protein interactions, post-translational modifications, and specific protein localization within tissue samples, with applications primarily in oncology research. The company's products and services aim to provide high-resolution spatial context for protein function, empowering researchers with deeper insights into disease mechanisms and drug development. Despite being a private company with limited disclosed financial or pipeline details, Navinci has established a niche in the rapidly growing spatial proteomics market, which is attracting increasing interest from pharmaceutical companies and academic institutions. The company's focus on protein interaction networks sets it apart from competitors, offering a unique value proposition for understanding complex biological systems. With a strong foundation in Uppsala's life science cluster, Navinci is poised for growth through strategic partnerships and product expansion.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with major pharma for oncology target validation60% success
• Q1 2026Launch of expanded multiplexing panel for Naveni platform75% success
• Q4 2025Series A funding round to accelerate commercial expansion50% success